Advertisement

Topics

Principia Biopharma Inc. Company Profile

06:03 EST 17th December 2018 | BioPortfolio

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital. For more information, please visit the company's website at www.principiabio.com.


News Articles [1347 Associated News Articles listed on BioPortfolio]

Principia Biopharma Reports Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company, Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing t...

Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer

- Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasda...

Principia Biopharma to Present at 27th Annual Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma to Present at 2018 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapi...

Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing ...

Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program

- Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of starting PRN1008 - - Demonstrated sustained clinical efficacy at 12 weeks of ...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the inte...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeut...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [147 Associated Companies listed on BioPortfolio]

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "Principia Biopharma Inc." on BioPortfolio

We have published hundreds of Principia Biopharma Inc. news stories on BioPortfolio along with dozens of Principia Biopharma Inc. Clinical Trials and PubMed Articles about Principia Biopharma Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Principia Biopharma Inc. Companies in our database. You can also find out about relevant Principia Biopharma Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record